Benefit from Almonertinib after Osimertinib treat EGFR 19 exon deletion NSCLC induced Severe rash: a case report-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Benefit from Almonertinib after Osimertinib treat EGFR 19 exon deletion NSCLC induced Severe rash: a case report

Published:2023-11 Issue: Volume: Page:1-9
ISSN:1120-009X
Container-title:Journal of Chemotherapy
language:en
Short-container-title:Journal of Chemotherapy

Author:

Zhang Qichen¹,Xie Peng²,Hou Xiaoming³,Zhao Chengpeng³,Duan Ling³,Qiao Hui³⁴^ORCID

Affiliation:

1. University of Lanzhou of the First School of Clinical Medicine, Lanzhou, China

2. Department of Radiation Oncology, The First Hospital of Lanzhou University, Lanzhou, China

3. Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, China

4. School of Life Sciences, Lanzhou University, Lanzhou, China

Funder

Organization Department of CPC Gansu provincial Party committee

Lanzhou Science and Technology Bureau

Gansu Provincial Department of Science and Technology

Publisher

Informa UK Limited

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/1120009X.2023.2276574

Reference38 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

3. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

4. Molecular diagnostics and targeted therapies in non-small cell lung ca ncer (NSCLC): an update;Jonna S;Discov Med,2019

5. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple drug;Reactions Weekly;2024-08-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3